-
Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ciltacabtagene Autoleucel Injection (trade name: 卡卫荻/Carvykti), of Nanjing Legend Biotech Co., Ltd. is approved for marketing with conditions by China NMPA.
-
Vunakizumab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Vunakizumab Injection (trade name: 安达静) of Suzhou Suncadia Biopharmaceuticals Co., Ltd. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy.
-
Xeligekimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Xeligekimab Injection (trade name: 金立希/Jin Li Xi) of Chongqing Genrix Biopharmaceutical Co., Ltd. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy.
-
Stapokibart Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Stapokibart Injection (trade name: 康悦达) of Chengdu Kangnuoxing Biopharma, Inc. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis in adults who are inadequately controlled by topical medications or for whom topical medications are not indicated.
-
Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug, Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) (trade name: 鼎优乐/XACDURO) of Entasis Therapeutics, Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Ivonescimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ivonescimab Injection (trade name: 依达方) of Akeso Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
